Monopar Therapeutics (MNPR)
(Delayed Data from NSDQ)
$63.29 USD
-2.96 (-4.47%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $65.18 +1.89 (2.99%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth B Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MNPR 63.29 -2.96(-4.47%)
Will MNPR be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for MNPR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MNPR
Wall Street Analysts Predict a 51.26% Upside in Monopar Therapeutics (MNPR): Here's What You Should Know
Here's Why Momentum in Monopar Therapeutics (MNPR) Should Keep going
MNPR: What are Zacks experts saying now?
Zacks Private Portfolio Services
MNPR Stock Skyrockets 384% in 3 Months After Deal With AZN
What Awaits These 4 Biotech Stocks That More Than Doubled in 2024
Here's What Could Help Monopar Therapeutics (MNPR) Maintain Its Recent Price Strength
Other News for MNPR
MNPR forms Boomer Buy Setup on September 20
Jack-in-the-box Bullish appears for MNPR after 0.59% move
MNPR makes New 52 Week Closing High on September 18
New 52 Week Closing High appears for MNPR after 4.61% move
Raymond James Reaffirms Their Buy Rating on Monopar Therapeutics Inc (MNPR)